Delcath has announced that abstracts summarising the data from two European studies of treatment with the Delcath Hepatic Chemosat Delivery System will be presented at the upcoming Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meeting (to be held in Lisbon, Portugal, 26–30 September).
The abstracts are: “Safety and efficicacy of the Delcath second generation filter in percutaneous hepatic perfusion with melphalan for unresectable hepatic metastases of colorectal cancer and uveal melanoma”, a study conducted at the Netherlands Cancer Institute by MC Burgmans and colleagues and “Lessons and early results from the largest single-centre experience in Europe of treating ocular melanoma liver metastases with chemosaturation via percutaneous hepatic perfusion, a study conducted at Southampton University, UK, by G Hickson and colleagues.
Delcath’s proprietary melphalan hydrochloride for injection for use with the Delcath Hepatic Delivery System is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. In April 2012, the company obtained authorisation to affix a CE mark to the second-generation system, which is currently marketed in Europe as a device under the trade name Delcath Hepatic Chemosat Delivery System for melphalan. In the USA, the system is considered a combination drug and device product and is regulated as a drug by the US FDA. It has not been approved for sale in the USA.
Delcath recently also announced that Jennifer Simpson was named president and CEO by the company’s Board of Directors. Simpson has served as interim president and CEO of Delcath since September 2014 and as interim co-president and co-CEO from September 2013 to September 2014.
